

Tip Sheet


Ordering Covid-19 Antibody Infusions - ASAP

Audience: ED Physicians
Topic: Covid-19 Antibody Infusion
Subject: Ordering Covid-19 Antibody Infusion
Application: ASAP
Revision Date: 8/26/2021


1. It is currently available as an Order Set. Keywords such as “covid”, “infusion”, or “covid infusion” can be used for searching the Epic Database.



2. The available selection is “ED COVID-19 Antibody Infusions” with an Order Set type for patients that will have their transfusion in the ED.



3. The available selection is “COVID-19 Antibody Infusion - outpatient” with an Order Set type for patients that will have their transfusion as an outpatient in the Infusion department.



4. Choose the infusion you would like to administer.

▼ Nursing

Due to resistance to the P.1 variant, bamlanivimab/etesevimab is no longer recommended for treatment of COVID-19 in Illinois as of May 4, 2021. Please order casirivimab/imdevimab if monoclonal antibody treatment is needed.

▼ COVID-19 Antibody Drugs

- Casirivimab/Imdevimab Nursing + Medication Orders

5. The Order Set for this infusion contains additional orders pertaining to infusion reactions, patient safety precautions, & information/consents. Please ensure the patient criteria order details is completed.

Casirivimab/Imdevimab Criteria Accept Cancel

Priority: **Routine**

Process Instructions: The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product casirivimab/imdevimab for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization. The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40kg) at higher risk for progression to severe COVID-19. High risk is defined as patients meeting at least one of the following criteria.

- Have a body mass index (BMI) greater than 25
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are 65 years of age or older

1 Is this an adult patient over 40kg who has tested positive for COVID-19 with mild to moderate symptom onset within the past 10 days and not requiring hospitalization?

1 Is patient high risk to progress to severe COVID-19 due to at least one of the following risk factors?
 BMI 25 or greater Diabetes Age 65 or greater Chronic kidney disease
 Immunosuppressive disease Currently on immunosuppressive treatment Pregnancy
 Cardiovascular disease or hypertension Chronic lung disease Sickle cell disease
 Neurodevelopmental disorders Medical-related technological dependence Other

1 Does patient require supplemental oxygen?

1 Has patient been educated on Casirivimab/Imdevimab EUA fact sheet and understands the risks and benefits?

Comments: [+ Add Comments](#)

Next Required Accept Cancel

COVID-19 Antibody Drugs

- Casirivimab/Imdevimab Nursing + Medication Orders
 - Nursing
 - Casirivimab/Imdevimab Criteria
 - Is this an adult patient over 40kg who has tested positive for COVID-19 with mild to moderate symptom onset within the past 10 days and not requiring hospitalization? Yes
 - Is patient high risk to progress to severe COVID-19 due to at least one of the following risk factors? BMI 25 or greater
 - Does patient require supplemental oxygen? Yes
 - Is this an increase over the baseline status? No
 - Has patient been educated on Casirivimab/Imdevimab EUA fact sheet and understands the risks and benefits? Yes
 - Informed Consent received and Fact Sheet for Patients, Parents and Caregivers reviewed with the patient Accept Cancel
 - Reference Links: [Casirivimab/Imdevimab Fact Sheet](#) [Casirivimab/Imdevimab Consent Form](#)
 - Comments: [Fact sheet and Consent are also located in Optio](#)
 - Monitor for infusion reaction
 - Routine, Continuous, Starting today at 1845, Until Sp
 - Monitor patient for infusion reaction: fever, difficulty breathing, chest pain or discomfort, weakness, altered mental status, rash including urticaria, pruritus, myalgia, etc.
 - Contact provider for infusion reaction
 - Routine, Until discontinued, Starting today at 1845, U
 - Monitor patient during infusion and 1 hour after infusion
 - Routine, Continuous, Starting today at 1845, Until Sp
 - Vital Signs
 - Routine, Every 15 min, First occurrence today at 1845
 - Vitals every 15 minutes during infusion, and every 15
 - Pulse Oximetry

Next Required Accept Cancel

sodium chloride 0.9 % infusion
 30 mL/hr, intravenous, Continuous, Starting today

casirivimab/imdevimab in NS IVPB 1,200 mg
 1,200 mg, intravenous, at 309.7 mL/hr, Administer
 Dose=Casirivimab 600mg + Imdevimab 600mg ;
 Must use 0.2-0.22 micron filter for administration.

Vital Signs
 Routine, Every 15 min, First occurrence today at 1845
 Vitals every 15 minutes during infusion, and every 15

